These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32816297)

  • 1. [Epidemiology of hallucinogenic drug use in the Netherlands].
    van Laar MW; van Miltenburg CJA
    Tijdschr Psychiatr; 2020; 62(8):684-692. PubMed ID: 32816297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of psychedelics in the Czech Republic: results of recent population surveys.
    Chomynová P; Kočárová R; Kňažek F; Plevková M; Bláhová B; Valeš K; Mravčík V
    Cent Eur J Public Health; 2022 Sep; 30(3):144-153. PubMed ID: 36239361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.
    Palamar JJ; Acosta P; Sherman S; Ompad DC; Cleland CM
    Am J Drug Alcohol Abuse; 2016 Nov; 42(6):624-632. PubMed ID: 27315522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
    Palamar JJ; Martins SS; Su MK; Ompad DC
    Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.
    Winstock AR; Kaar S; Borschmann R
    J Psychopharmacol; 2014 Jan; 28(1):49-54. PubMed ID: 24284475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurotrophic mechanisms of psychedelic therapy].
    Corne R; Mongeau R
    Biol Aujourdhui; 2019; 213(3-4):121-129. PubMed ID: 31829932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in drug use among electronic dance music party attendees in New York City, 2016-2019.
    Palamar JJ; Keyes KM
    Drug Alcohol Depend; 2020 Apr; 209():107889. PubMed ID: 32050110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in DMT and other tryptamine use among young adults in the United States.
    Palamar JJ; Le A
    Am J Addict; 2018 Oct; 27(7):578-585. PubMed ID: 30260086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.
    Lake S; Lucas P
    Int J Drug Policy; 2024 Aug; 130():104507. PubMed ID: 38936219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with the use of psychedelics, ketamine and MDMA among sexual and gender minority youths in Canada: a machine learning analysis.
    Dharma C; Liu E; Grace D; Logie C; Abramovich A; Mitsakakis N; Baskerville B; Chaiton M
    J Epidemiol Community Health; 2024 Mar; 78(4):248-254. PubMed ID: 38262735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An age-period-cohort analysis of trends in psychedelic and ecstasy use in the Australian population.
    Chan G; Sun T; Lim C; Yuen WS; Stjepanović D; Rutherford B; Hall W; Johnson B; Leung J
    Addict Behav; 2022 Apr; 127():107216. PubMed ID: 34979428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use and abuse of dissociative and psychedelic drugs in adolescence.
    Bates MLS; Trujillo KA
    Pharmacol Biochem Behav; 2021 Apr; 203():173129. PubMed ID: 33515586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
    Mellner C; Dahlen M; Simonsson O
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.